Takashi Nakamura (T Nakamura)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 7

Top Topics

Metabolic Syndrome

Top Venues

Nutrition & diabetes

Diabetes, metabolic syndrome and obesity : targets and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Ken Sato, Atsushi Naganuma, Tamon Nagashima, Yosuke Arai, Yuka Mikami, Yuka Nakajima, Yuki Kanayama, Tatsuma Murakami, Sanae Uehara, Daisuke Uehara, Yuichi Yamazaki, Takayo Murase, Takashi Nakamura, Masashi Namikawa
A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases. Biomedicines 11 (5) (2023)
Megumi Shimizu, Ryo Naito, Akihiro Sato, Sayaki Ishiwata, Shoichiro Yatsu, Jun Shitara, Hiroki Matsumoto, Azusa Murata, Takao Kato, Shoko Suda, Masaru Hiki, Masanari Kuwabara, Takayo Murase, Takashi Nakamura, Takatoshi Kasai
Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease. Nutrients 15 (20) (2023)
Seigo Akari, Takashi Nakamura, Kenichi Furusawa, Yuichi Miyazaki, Kazuomi Kario
The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data. Journal of clinical hypertension (Greenwich, Conn.) 24 (8) (2022)
Takeo Ishii, Tomohiro Kumagae, Hiromichi Wakui, Shingo Urate, Shohei Tanaka, Eriko Abe, Toru Suzuki, Takahiro Yamaji, Sho Kinguchi, Ryu Kobayashi, Kotaro Haruhara, Takashi Nakamura, Shuzo Kobayashi, Kouichi Tamura
Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy. FEBS open bio 11 (2) (2021)
Takashi Nakamura, Mai Nampei, Takayo Murase, Etsuko Satoh, Seigo Akari, Noriaki Katoh, Hiroki Mizukami
Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice. Nutrition & diabetes 11 (1) (2021)
Takashi Nakamura, Hitomi Tanimoto, Masayuki Okamoto, Mitsuaki Takeuchi, Yoshiharu Tsubamoto, Hitoshi Noda
GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice. Diabetes, metabolic syndrome and obesity : targets and therapy 14 (2021)
Takashi Nakamura, H Tanimoto, Y Mizuno, M Okamoto, M Takeuchi, Y Tsubamoto, H Noda
Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice. Obesity science & practice 4 (2) (2018)